New antidepressant drugs

Here are some new antidepressant drugs that have been approved or are in development:

Approved in recent years:

  1. Vortioxetine (Trintellix): Approved in 2013, this drug is a serotonin modulator that works by affecting multiple neurotransmitters, including serotonin, dopamine, and norepinephrine.
  2. Bupropion (Aplenzin): Approved in 2009, this drug is a norepinephrine-dopamine reuptake inhibitor (NDRI) that is also used to treat smoking cessation.
  3. Vilazodone (Viibryd): Approved in 2011, this drug is a serotonin antagonist and reuptake inhibitor (SARI) that is used to treat major depressive disorder.
  4. Lurasidone (Latuda): Approved in 2015, this drug is a second-generation antipsychotic that is also used to treat major depressive disorder.
  5. Nalmefene (Selincro): Approved in 2013, this drug is a gamma-aminobutyric acid (GABA) receptor antagonist that is used to treat alcohol dependence.

In development:

  1. Rapastinel (GLYX-13): A glutamate receptor modulator that is being developed by Johnson & Johnson to treat major depressive disorder.
  2. Esketamine (Spravato): A ketamine derivative that is being developed by Janssen Pharmaceuticals to treat treatment-resistant depression.
  3. Lorcaserin (Belviq): A serotonin 2C receptor agonist that is being developed by Eisai to treat major depressive disorder.
  4. Pitolisant (Nourianz): A histamine H3 receptor antagonist that is being developed by Biogen to treat major depressive disorder.
  5. AZD6769: A selective serotonin reuptake inhibitor (SSRI) that is being developed by AstraZeneca to treat major depressive disorder.
  6. BPN-14673: A serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI) that is being developed by Biogen to treat major depressive disorder.
  7. CERC-301: A glutamate receptor modulator that is being developed by Cerecor to treat major depressive disorder.
  8. GSK-932121: A serotonin receptor modulator that is being developed by GlaxoSmithKline to treat major depressive disorder.

Please note that the development and approval process for new antidepressant drugs can be lengthy and complex, and not all drugs that are in development will ultimately be approved for use. Additionally, the effectiveness and safety of these new drugs are still being studied and may not be fully understood at this time.